Dr orlando icaza weight loss clinic - dr orlando icaza weight loss clinic

Dr orlando icaza weight loss clinic
(2016) Psychopharmacology in Primary Care Settings. Lesage, M. Van Dorn, Leslie Citrome, Rene S. Hughes, Brinda Rana, Sophia Vinogradov, Gregory A. CrossRef 269 Dorien H Nieman, Patrick D McGorry. CrossRef 357 Katherine L Wisner, Christof Schaefer. 2015. (2017) Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials. (2015) Sleep in Schizophrenia. Grimm, S. 2015. Shajahan. (2015) Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. (2017) Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study. A sensitivity analysis of the Cox model for the discontinuation of treatment for any cause evaluated the effects of potentially important baseline covariates and their interaction with the treatment group. CrossRef 10 A C Mitchell, B Javidfar, V Pothula, D Ibi, E Y Shen, C J Peter, L K Bicks, T Fehr, Y Jiang, K J Brennand, R L Neve, J Gonzalez-Maeso, S Akbarian. McDaid, S. Leboyer, F. Hyperglycemia Secondary to Nondiabetic Conditions and Therapies. Concerns about potential prolongation of the corrected QT interval with ziprasidone and of cataracts with quetiapine were not realized in this study. CrossRef 231 Hani Raoul Khouzam. Fraga, Stela M. However, olanzapine was associated with greater weight gain and increases in glycosylated hemoglobin, cholesterol, and triglycerides, changes that may have serious implications with respect to medical comorbidity such as the development of the metabolic syndrome. CrossRef 286 Yoshinori Takeuchi, Kazuhiro Kajiyama, Chieko Ishiguro, Yoshiaki Uyama. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. CrossRef 161 Thomas P White, Rebekah Wigton, Dan W Joyce, Tracy Collier, Alex Fornito, Sukhwinder S Shergill. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 73 Fang Fang, Hongwei Sun, Zuowei Wang, Ming Ren, Joseph R. (2015) Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. CrossRef 393 Daniela Peixoto, Abel Locati, Carolina S. (2015) Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. A. (2015) Metabolic abnormalities among people diagnosed with schizophrenia: a literature review and implications for mental health nurses. : IMS Health, January 2001-December 2004. Miller. (2016) New drug developments in psychosis: Challenges, opportunities and strategies. CrossRef 238 Ayaka Tatara, Saki Shimizu, Atsushi Masui, Miyuki Tamura, Shoko Minamimoto, Yuto Mizuguchi, Midori Ochiai, Yusuke Mizobe, Yukihiro Ohno. Tsapakis, Trisevgeni Dimopoulou, Frank I. (2016) Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. CrossRef 388 Davide Amato. Alafaireet, Howard Houghton. Adobe Flash Player is required to view this feature. Adobe Flash Player is required to view this feature. Approaches to multisite clinical trials: the National Institute of Mental Health perspective. (2016) THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Einarson, Hanna Pudas, Pushpendra Goswami, Kristel van Impe, Basil G. Objectives and Outcomes We hypothesized that there would be significant differences in the overall effectiveness of olanzapine, perphenazine, quetiapine, risperidone, and ziprasidone in treating schizophrenia that reflected variations in efficacy and tolerability. Thus, the P value for the overall interaction between time and treatment excludes the ziprasidone group and is given separately for the ziprasidone cohort. Schwartz, Stephenie Scully, Jean-Philippe Langevin, Shana Spangler, Arkady Korotinsky, Kevin Jou, Andrew Leuchter. CrossRef 80 Mark S Bauer, Christopher J Miller, Mingfei Li, Laura A Bajor, Austin Lee. CrossRef 136 Ashwin Weng Seng Chee, Edimansyah bin Abidin, Swapna Kamal Verma. Aparasu, Satabdi Chatterjee, Hua Chen. Kelly. CrossRef 3 Zhiguo Li. (2015) Identification and management of tardive dyskinesia: A case series and literature review. Snyder, Jos Prickaerts, Marie-Louise Wadenberg, Lei Zhang, Hailin Zheng, Wei Yao, Sven Akkerman, Hongwen Zhu, Joseph P. Insel. Dechairo. (2016) Ricerca e impiego degli psicofarmaci. CrossRef 93 Gagan Fervaha, Ofer Agid, George Foussias, Ishraq Siddiqui, Hiroyoshi Takeuchi, Gary Remington. The NMDA Receptor and Schizophrenia. Guest, Bernhard Bogerts, Sabine Bahn. International Journal of Psychiatry in Clinical Practice 19:2, 99-105. CrossRef 342 Tim Slade, Louisa Degenhardt, Philip S. -F. D. Adobe Flash Player is required to view this feature. (2016) Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. (2015) Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. D. Benson. CrossRef 178 G. CrossRef 319 Dorien H Nieman. Roodbol. Berndt, Marcela Horvitz-Lennon, Sharon-Lise Normand, Julie M. Davis. (2016) Neurocognitive impairment in the deficit subtype of schizophrenia. 2017. CrossRef 341 Holly Moore, Trevor W. CrossRef 293 Minji Sohn, Jeffery Talbert, Karen Blumenschein, Daniela Claudia Moga. Postolache. Journal of Pharmaceutical Health Care and Sciences 1:1. The number of patients included at each assessment time point declined over time. (2016) The latent structure of psychiatric symptoms across mental disorders as measured with the PANSS and BPRS-18. It is important to note that the differences between olanzapine and perphenazine were moderate. Klingaman, Li Juan Fang, Stephanie Tapscott, Mary Brighid Walsh. Furberg. CrossRef 232 Ahmed El-Missiry, Amira Elbatrawy, Marwa El Missiry, Dalia Abdel Moneim, Ramy Ali, Heba Essawy. (2015) The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Daly, A. Paulk, Ishita Basu, Ali Yousefi, Samuel Zorowitz, Anna Gilmour, Afsana Afzal, Thilo Deckersbach, Sydney S. Psychotropic drugs. Ziprasidone was the only study drug associated with improvement in each of these metabolic variables. (2015) Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. (2016) Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. T. (2015) Racial Disparities in Community Outcomes Among Individuals with Schizophrenia and Cooccurring Substance Use Disorders. (2015) Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials. 2015. The key secondary outcomes were the specific reasons for the discontinuation of treatment (e. (2017) Rational Use of Second-Generation Antipsychotics for the Treatment of ICU Delirium. (2015) Serotonin in antipsychotic drugs action. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. g. Analyses involving the ziprasidone group were limited to the cohort of patients who underwent randomization after the addition of ziprasidone to the study (the ziprasidone cohort). Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. M. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Evaluating interventions. (2016) Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. C. Benes. (2015) Living with antipsychotic medication side-effects: The experience of Australian mental health consumers. Although haloperidol is the first-generation agent most commonly used for comparison, we chose to use perphenazine because of its lower potency and moderate side-effect profile. CrossRef 220 Jayesh Kamath, Sundeep Virdi, Andrew Winokur. Bogue, Sur Herrera Paredes, Scott Yourstone, Ian M. Langmead, C. (2016) Targeting the Endocannabinoid System in Psychiatric Illness. Joffe. (2015) Methodological Comments: McFarlane et al. CrossRef 359 Andrew McKean, Erik Monasterio. CrossRef 204 Marwa Abdel-Rahman Sultan, Reem El Sayad Hashem, Nesreen Mohamed Mohsen, Doaa Helmy Barakat, Ramy Ali Ryad, Afaf Hamed Khalil. (2015) Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. Within this limited range of effectiveness, olanzapine appeared to be more effective than the other drugs studied, and there were no significant differences in effectiveness between the conventional drug perphenazine and the other second-generation drugs. (2015) The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. CrossRef 332 Yu-Hsuan Wu, Chun-Yang Lai, Yu-San Chang. De Hert, C. CrossRef 314 Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, Jimmy Lee, George Foussias, Gary Remington. McClave, Keith R. (2016) The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. (Accessed August 26, 2005, at ) 21 Harrington C, Gregorian R, Gemmen E, et al. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2015) The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: An analysis of the CATIE Schizophrenia Trial. (2015) The Bidirectional Relation Between Psychiatric Disorders With Selected Cardiovascular and Endocrinal Diseases: An Egyptian Perspective. Palaguachi, Dmytro Mikhnev, Rujia Teng, Rebecca Andridge, Marilyn Logan, Merlin G. Adobe Flash Player is required to view this feature. Abstract Background The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. Boscarino, Zahra Daar, Glenn S. D. 2015. PANSS scores can range from 30 to 210, with higher scores indicating more severe psychopathology. C. (2016) Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. A meta-analysis of the efficacy of second-generation antipsychotics. Leonard, Siegfried Kasper. (2016) Mental Health Issues and Special Care Patients. M. (2016) The effects in rats of lisdexamfetamine in combination with olanzapine on mesocorticolimbic dopamine efflux, striatal dopamine D2 receptor occupancy and stimulus generalization to a d-amphetamine cue. Uslaner. Swartz. (2016) Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder. Sellers, Marvin S. White. Pettit, Jeffrey Stoddard, Jalpa A. (2015) The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Wood, Jeffrey S. Fountoulakis, Xenia Gonda, Melina Siamouli, Katerina Moutou, Zoe Nitsa, Brian E. (2016) Sleep and Schizophrenia. 0 mg per day) for up to 18 months. CrossRef 255 Rene S Kahn, Amalia Giannopoulou. : Lewin Group, 2000. (2016) Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CrossRef 22 Ana SayuriYamagata, Elisa Brietzke, Joshua Rosenblat, Ron Kakar, Roger S. CrossRef 346 Shinichiro Nakajima, Hiroyoshi Takeuchi, Gagan Fervaha, Eric Plitman, Jun Ku Chung, Fernando Caravaggio, Yusuke Iwata, Yukiko Mihashi, Philip Gerretsen, Gary Remington, Benoit Mulsant, Ariel Graff-Guerrero. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Journal of the International Neuropsychological Society 21:06, 436. (2015) Prevalence and predictors of medication non-adherence among Chinese patients with first-episode psychosis. Patients with current tardive dyskinesia could enroll, but the randomization scheme prevented their assignment to treatment with perphenazine. H. (2015) Sleep Disturbances in Schizophrenia. CrossRef 367 M. Wittekind, Martina Fieker, Ulrike Heitz, Ruth Veckenstedt, Francesca Bohn, Steffen Moritz. CrossRef 8 Yoonsun Mo, Felix K. 2016. Free Full Text 59 K. Reviews from certified professional resume expert. CrossRef 100 Daniel Almirall, Andrea Chronis-Tuscano. (2015) Effects of high-intensity aerobic exercise on psychotic symptoms and neurocognition in outpatients with schizophrenia: study protocol for a randomized controlled trial. References References 1 Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Mitchell, Behnam Javidfar, Aslihan Dincer, Royce Park, Jennifer Wiseman, Paula L. Van Dorn, L. CrossRef 272 Steve Kisely, Emily Sawyer, Gail Robinson, Dan Siskind. (2015) Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia. CrossRef 379 Antonio Ventriglio, Antonello Bellomo, Dinesh Bhugra. CrossRef 48 R-R Wu, F-Y Zhang, K-M Gao, J-J Ou, P Shao, H Jin, W-B Guo, P K Chan, J-P Zhao. Eskandar. (2015) Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: An introduction to this Special Issue of schizophrenia research. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Moreover, olanzapine was associated with greater increases in weight and indexes of glucose and lipid metabolism than the other treatments. Pollock. (2016) Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Adobe Flash Player is required to view this feature. CrossRef 343 Zahinoor Ismail, Robert Granger, Bruce G. Marshak, Susan Garavaglia, Bryan M. Adobe Flash Player is required to view this feature. Wennogle. , Marvin S. CrossRef 202 Dong-Wook Kim, Kwon-Yeon Weon, Eon-Pyo Hong, Eun Kyoung Chung, Kyung-Tae Lee. How clinicians, patients, families, and policymakers evaluate the trade-offs between efficacy and side effects, as well as drug prices, will determine future patterns of use. CrossRef 345 Marta Bosia, Alessandro Pigoni, Roberto Cavallaro. McEvoy, Brian J. The Journal of Nervous and Mental Disease 203:3, 187-193. Glenthoj, M. The World Journal of Biological Psychiatry 16:1, 45-56. Scores for the PANSS and CGI Scale were determined at study entry and 1, 3, 6, 9, 12, 15, and 18 months after randomization. (2015) Association of a Schizophrenia Risk Variant at the. (2015) Increasing Endocannabinoid Levels in the Ventral Pallidum Restore Aberrant Dopamine Neuron Activity in the Subchronic PCP Rodent Model of Schizophrenia. Annals of the New York Academy of Sciences 1344:1, 105-119. Perphenazine for schizophrenia. CrossRef 398 Onur Baser, Lin Xie, Jacqueline Pesa, Mike Durkin. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Scott Stroup, M. Miller. This outcome indicates that antipsychotic drugs, though effective, have substantial limitations in their effectiveness in patients with chronic schizophrenia. (2016) Genome-Wide Association Study Suggested the. Falls Church, Va. Gerhard. W. (2017) Sedative effect of Clozapine is a function of 5-HT2A and environmental novelty. I. (2016) Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus. Underwood, C. A Bibliometric Study of 45 Years of Research in International Context. Results Characteristics and Disposition of Patients Table 1 Table 1 Baseline Demographic and Clinical Characteristics of Randomized Patients. Treatments for delusional disorder. (2015) Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Only risperidone was associated with a substantial increase in prolactin levels. The correlation of the repeated measures within each patient was modeled with the use of a random subject intercept and an unstructured covariance matrix. CrossRef 188 Ashli Owen-Smith, Christine Stewart, Carla Green, Brian K. McGuire, A. Adobe Flash Player is required to view this feature. The overall difference among the olanzapine, quetiapine, risperidone, and perphenazine groups was evaluated with the use of a test with 3 degrees of freedom (df). All patients assigned to twice-daily dosing received five identical-appearing capsules to begin treatment. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. Lodge. Tamminga, Sharon Mates, Kimberly E. (2017) Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. (2016) Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. RSC Adv. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. 8 to 10 percent). Adobe Flash Player is required to view this feature. CrossRef 196 Ajay Jajodia, Harpreet Kaur, Kalpana Kumari, Neha Kanojia, Meenal Gupta, Ruchi Baghel, Mamta Sood, Sanjeev Jain, Rakesh K. (2015) Antipsychotic medication in schizophrenia: a review. M. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. (2016) The prevalence and risk factors of the metabolic syndrome in inpatients with intellectual disability. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. (2015) Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. Adobe Flash Player is required to view this feature. Adobe Flash Player is required to view this feature. CrossRef 36 Xiang Cong Tham, Huiting Xie, Cecilia Mui Lee Chng, Xin Yi Seah, Violeta Lopez, Piyanee Klainin-Yobas. Ellenbroek, Tim Karl. (2016) Crosstalk Between Insulin and Dopamine Signaling: A Basis for the Metabolic Effects of Antipsychotic Drugs. CrossRef 197 Jin-Woo Cho, Won-Hyoung Kim, Jun-Hwan Shin, Ji-Hyun Kim, Jeong-Seop Lee, Jae-Nam Bae, Chul-Eung Kim. (2016) Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. 2015. CrossRef 97 Sangeeta Dey, David B Menkes, Zuzana Obertova, Sreemanti Chaudhuri, Graham Mellsop. Czobor. Adobe Flash Player is required to view this feature. 24-28 The protocol was made available to the public for comment, and a committee of scientific experts, health care administrators, and consumer advocates critiqued the study under the auspices of the NIMH. Chadda, Ritushree Kukreti. , M. sites and randomly assigned to receive olanzapine (7. Martinsen, Jon Mordal, Gunnar Morken, Jens Egeland. CrossRef 310 Quentin J. (2015) Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. Breggin. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Ndukwe, Prasad S. D. Albert. (2016) Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. CrossRef 254 Antonio Ventriglio, Alessandro Gentile, Eleonora Stella, Antonello Bellomo. Patel, Toshi Furukawa, Andrea Cipriani, John Geddes, John M. Janardhan Reddy. Smyth. (2015) Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. J. P. CrossRef 395 Markus Dold, Martin Aigner, Rupert Lanzenberger, Siegfried Kasper. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Adobe Flash Player is required to view this feature. (2016) Core Concepts Involving Adverse Psychotropic Drug Effects. (2015) A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome. CrossRef 242 Jun Soo Kwon, Sung Nyun Kim, Jaewook Han, Sang Ick Lee, Jae Seung Chang, Jung-Seok Choi, Heon-Jeong Lee, Seong Jin Cho, Tae-Youn Jun, Seung-Hwan Lee, Changsu Han, Kyoung-Uk Lee, Kyung Kyu Lee, EunJung Lee. CrossRef 244 Bartosz Helfer, Stefan Leucht, Philipp H Rothe, Myrto T Samara, Stefan Leucht. CrossRef 300 John Lally, James H. We used broad inclusion and minimal exclusion criteria and allowed the enrollment of patients with coexisting conditions and those who were taking other medications. Scores for the PANSS can range from 30 to 210, with higher scores indicating more severe psychopathology. Psychopharmacology for Children and Adolescents: A Paradigm Shift. Fudala, Philip Twumasi-Ankrah, Alex Kouassi, Christian Heidbreder. Statistical Analysis Randomized patients who received at least one dose of study medication made up the intention-to-treat population. Pantelis, P. Dibble, Yijuan Du, Anthony A. Yam. 2016. Giuffrida, D. Arango, W. (2016) Medication adherence in patients with schizophrenia. Clinical Trial Design Challenges in Mood Disorders, 49-57. (2015) Equivalence of kernel machine regression and kernel distance covariance for multidimensional phenotype association studies. (2017) Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia. (2015) Searching human brain for mechanisms of psychiatric disorders. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Adobe Flash Player is required to view this feature. (2016) Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. CrossRef 298 M. CrossRef 317 Alok Madan, Cory R Walker, Benjamin Weinstein, J Christopher Fowler. CrossRef 307 Gagan Fervaha, Hiroyoshi Takeuchi, Jimmy Lee, George Foussias, Paul J Fletcher, Ofer Agid, Gary Remington. Barreiro, Carlos A. CrossRef 362 Gagan Fervaha, Ishraq Siddiqui, George Foussias, Ofer Agid, Gary Remington. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2016) Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P Full Text of Results. (2015) Person-centered care planning and service engagement: a study protocol for a randomized controlled trial. International Journal of Psychiatry in Clinical Practice, 1-3. Vanover, Robert Davis, Peng Li, Sharon Mates, Lawrence P. The primary aim was to delineate differences in the overall effectiveness of these five treatments. Swartz, M. (2016) Different mechanisms of risperidone result in improved interpersonal trust, social engagement and cooperative behavior in patients with schizophrenia compared to trifluoperazine. Jones, Yu-Wen Li, Michele Matchett, Gail Mattson, Regina Miller, Kenneth S. CrossRef 148 Stefano Porcelli, Oriana Bianchini, Giovanni De Girolamo, Eugenio Aguglia, Luciana Crea, Alessandro Serretti. Stroup, C. J. Smith, Jason M. J. M. Adobe Flash Player is required to view this feature. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Mehta, Daya Ram. Quetiapine was associated with a higher rate of anticholinergic effects than were the other drugs (31 percent vs. The World Journal of Biological Psychiatry 17:3, 210-220. Scammells, C. Adobe Flash Player is required to view this feature. Kilbourne, Martha Gerrity, Stephen Marder, Kousick Biswas, Paul Hicks, Lori L. (2016) Cardiovascular safety of antipsychotics: a clinical overview. CrossRef 336 Manit Srisurapanont, Sirijit Suttajit, Narong Maneeton, Benchalak Maneeton. Leddy-Stacy, Robert Rosenheck. Tueller, K. George Awad. Macek. Dima, M. Karpov, James Schuster. 05, the three atypical-drug groups were compared with each other by means of step-down or closed testing, with a P value of less than 0. (2015) Letter to the Editor: Concepts and methods when considering negative symptom course: a reply. CrossRef 402 Roberto Mandrioli, Michele Protti, Laura Mercolini. CrossRef 96 Edward Chia-Cheng Lai, Cheng-Yang Hsieh, Chien-Chou Su, Yea-Huei Kao Yang, Chin-Wei Huang, Swu-Jane Lin, Soko Setoguchi. CrossRef 228 Joke M. Swerdlow. Goldberg, Carrie L. CrossRef 146 Jordi Espadaler, Miquel Tuson, Jose Miguel Lopez-Ibor, Franciso Lopez-Ibor, Maria Ines Lopez-Ibor. S. A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. CrossRef 339 Seiya Miyamoto, David B. (2016) Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. Akbarian. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. CrossRef 366 H. (2015) Indications of atypical antipsychotics in the elderly. , Joseph P. The study was conducted between January 2001 and December 2004 at 57 clinical sites in the United States (16 university clinics, 10 state mental health agencies, 7 Veterans Affairs medical centers, 6 private nonprofit agencies, 4 private-practice sites, and 14 mixed-system sites). Fleury, A. As in other studies, we found that risperidone was associated with hyperprolactinemia and olanzapine was associated with substantial weight gain in addition to adverse changes in glucose and lipid metabolism — all features of the metabolic syndrome. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 6 Hung-Yu Chan, Yi-Ju Pan, Jiahn-Jyh Chen, Chiung-Hsu Chen. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Jackson Foster, Ralph L. The Neurobiology of Comorbid Drug Abuse in Schizophrenia and Psychotic Disorders. (2016) Three-month paliperidone palmitate - a new treatment option for schizophrenia. CrossRef 192 Gordon Harper, Peter Parry, Jared Ng, Shekhar Seshadri. Journal of Pharmacology and Experimental Therapeutics 359:2, 354-365. (2016) Comparative Physicochemical and Pharmacokinetic Properties of Quetiapine and Its Active Metabolite Norquetiapine. Schizophrenia: Metabolic Consequences. (2014) Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder. Kraemer. Thus, the P value for the overall interaction between time and treatment excludes the ziprasidone group and is given separately for the ziprasidone cohort. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. E. Demers, M. Khurshid, Robert Averbuch, Imran S. (2015) Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. (2016) Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors. McIntyre. Moga, Karen Blumenschein, Jeffery Talbert. (2015) Clotiapine in schizophrenia: a guide to its use. International Journal of Mental Health Nursing 24:6, 547-553. CrossRef 101 Miquel Bernardo, Miquel Bioque. Adobe Flash Player is required to view this feature. Delorme. (2016) Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. There were no significant differences among the groups in the incidence of new cataracts. U. R. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Balfour Sartor, Patrick F. 2016. The International Journal of Psychiatry in Medicine 51:2, 211-219. (2017) Factors associated with complete discontinuation of medication among patients with schizophrenia in the year after hospital discharge. (2015) Loxapine Add-on for Adolescents and Adults with Autism Spectrum Disorders and Irritability. (2016) Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. To minimize initial side effects, patients assigned to quetiapine began treatment by receiving one 100-mg capsule on days 1 and 2, one twice daily on day 3, and one for the first dose of day 4. (2016) Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. Nasrallah, Rajiv Tandon. (2016) Antipsychotic medication side effect assessment tools: A systematic review. Dose could have been a factor in the performance of the various agents studied. CrossRef 65 Itaru Miura, Jian-Ping Zhang, Katsuhiko Hagi, Todd Lencz, John M. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2015) A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. There were no significant differences among the drugs in the time until discontinuation of treatment owing to intolerable side effects. Scores for the PANSS and CGI Scale were determined at study entry and 1, 3, 6, 9, 12, 15, and 18 months after randomization. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Correll. (2016) Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income. Adobe Flash Player is required to view this feature. Narayanaswamy, Suresh Bada Math, Y. (2016) A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications. (2016) Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia. (2016) The involvement of family members in the treatment of patients with schizophrenia. CrossRef 105 Toshihiko Kinoshita, Ya-Mei Bai, Jong-Hoon Kim, Mutsuo Miyake, Nobuyuki Oshima. CrossRef 374 S. patients without psychiatric illness. 2015. Free No hidden cost, resume builder is always free for all features. Conclusions The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Bingham, Richard Yanofsky. (2016) National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. (2016) Body mass index and blood glucose in psychiatric and general practice populations. Treatment groups were compared with use of Cox proportional-hazards regression models 29 stratified according to site, with adjustment for whether the patient had had an exacerbation of schizophrenia in the preceding three months and tardive dyskinesia status (for models excluding perphenazine). Adobe Flash Player is required to view this feature. -J. (2015) Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia. Media in This Article Figure 1 Enrollment and Outcomes. CrossRef 302 Jan Malte Bumb, Frank Enning, F Markus Leweke. Fleischhacker, B. CrossRef 281 Helena Chmura Kraemer. Fewer patients receiving quetiapine were prescribed anticholinergic drugs (3 percent vs. Wiesjahn, H. 2017. (2015) Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. Kahn, W. Frolova, E. Geriatric Psychiatry: Perceptions, Presentations, and Treatments. Rosebush, Michael F. Gallego, Majnu John, Jin Yu, Jean Addington, Mauricio Tohen, John M. CrossRef 239 Kotaro Hatta. Adobe Flash Player is required to view this feature. Mitchell, F. (2016) A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. Van Dorn, Kevin J. Modeling the Psychopathological Dimensions of Schizophrenia - From Molecules to Behavior, 303-324. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 267 G. Access and utilization of new antidepressant and antipsychotic medications. Send your resume to any one or job postings. Almeida, Regina C. Khandaker, B. Its rationale, design, and methods have been described previously. Savill, S. Ernst. Cho, Vanessa Torres-Llenza, Kaitlin Budnik, Lorenzo Norris. (2015) Psychotherapy and Psychosocial Treatment. (2015) Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition. (2016) The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study. Journal of Child and Adolescent Psychopharmacology 25:2, 150. The PANSS total scores and CGI Scale scores over time were compared among the groups with the use of a mixed model including the same fixed covariates as for the time to discontinuation, plus baseline value, time, the interaction between treatment and time, and the interaction between baseline value and time. Schneider. CrossRef 122 Omer Saatcioglu, Murat Kalkan, Nurhan Fistikci, Sakire Erek, Kasim Candas Kilic. (2016) Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Lieberman. Modeling the Psychopathological Dimensions of Schizophrenia - From Molecules to Behavior, 375-390. Estimates are from a mixed model, which assumed that data were missing at random. CrossRef 372 V. Kinney. Ziprasidone was added to the study after approximately 40 percent of patients had been enrolled. Moore, Curt D. CrossRef 361 Denis Rybin, Gheorghe Doros, Robert Rosenheck, Robert Lew. Patients with tardive dyskinesia were not assigned to perphenazine. (2016) Effects of olanzapine on LPS-induced inflammation in rat primary glia cells. MacCabe. Malhotra, Christoph U. (2015) Weight Gain on Antipsychotic Medication Is Associated With Sustained Use Among Veterans With Schizophrenia. Rosen, Susan Shakib, Lynn M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. S. M. Ziprasidone was added to the trial after approximately 40 percent of the patients had been enrolled. (2015) Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital. CrossRef 222 Victoria Stanhope, Janis Tondora, Larry Davidson, Mimi Choy-Brown, Steven C Marcus. (2015) A Typology of Community Violence Perpetration and Victimization Among Adults With Mental Illnesses. Adobe Flash Player is required to view this feature. Lincoln. (2016) Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia. (2015) Metakognitives Training bei Schizophrenie. Kapur, R. (2015) Oscillations and Neuronal Dynamics in Schizophrenia: The Search for Basic Symptoms and Translational Opportunities. CrossRef 344 Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, Jimmy Lee, George Foussias, Konstantine K. CrossRef 87 Kim S. Patient Driven Service Delivery Models in Mental Health Care. London: IMS Health, 2002. Secondary safety and tolerability outcomes, which were evaluated at months 1, 3, 6, 9, 12, 15, and 18, included the incidence of serious adverse events, the incidence of adverse events during treatment, the incidence of neurologic side effects, and changes in weight, electrocardiographic findings, and laboratory analytes. Correll. Schooler, Patricia Marcy, Somaia Mohamed, John M. Primary Care: Clinics in Office Practice 43:2, 327-340. Daly, Bo Liang, Lifeng Zhang, Xuan Li, Yun Li, Da-Ting Lin. The results for the other second-generation antipsychotic agents and the representative conventional drug, perphenazine, were similar in most respects. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Freedy. Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. (2015) Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients. S. shows the baseline demographic and clinical characteristics of the patients. (2015) Olanzapine promotes the accumulation of lipid droplets and the expression of multiple perilipins in human adipocytes. J. Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications. Swartz, Richard A. CrossRef 195 Ranganath D Rattehalli, Sai Zhao, Bao Guo Li, Mahesh B Jayaram, Jun Xia, Stephanie Sampson, Ranganath D Rattehalli. Adobe Flash Player is required to view this feature. Katzman, Melissa Furtado, Leena Anand. (2016) Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia. (2016) Treating refractory mental illness with closed-loop brain stimulation: Progress towards a patient-specific transdiagnostic approach. Macor, Andrew P. CrossRef 348 Kit Wa Sherry Chan, Men Heng Marian Wong, Christy Lai Ming Hui, Edwin Ho Ming Lee, Wing Chung Chang, Eric Yu Hai Chen. Jung, M. CrossRef 330 Lewei Allison Lin, Robert Rosenheck, Catherine Sugar, Arthur Zbrozek. Fleischhacker, P. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Bower, R. (2016) BDNF rescues prefrontal dysfunction elicited by pyramidal neuron-specific DTNBP1 deletion. Rose, P. K. Fitzgerald, Zafiris J. CrossRef 275 Marc De Hert, Jan Sermon, Paul Geerts, Kristof Vansteelandt, Joseph Peuskens, Johan Detraux. Bock, W. Lyseng-Williamson. Sexton, J. Discussion All second-generation antipsychotic drugs were included in phase 1 of this study except aripiprazole (which was approved by the FDA in November 2002) and clozapine, which was included in phase 2 for patients who discontinued phase 1 of treatment owing to lack of efficacy of the assigned drug. (2015) Augmented antipsychotic therapy with pantogam active in patients with schizophrenia. Heimesaat. Consequently, comparisons involving the perphenazine group were limited to patients without tardive dyskinesia, and comparisons involving the ziprasidone group were limited to the cohort of patients who underwent randomization after ziprasidone was added (the ziprasidone cohort). (2015) Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: A 2year follow-up study. Voruganti. 2015. (2015) Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. (2016) A longitudinal analysis of the overlap between violence and victimization among adults with mental illnesses. CrossRef 183 Jiamei Lian, Xu-Feng Huang, Nagesh Pai, Chao Deng. (2016) Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia. (2017) The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects. Hahn, Anthony C. 6:3, 2032-2045. 35 Lehman AF, Lieberman JA, Dixon LB, et al. Rujescu, S. The International Journal of Psychiatry in Medicine 49:1, 45-62. (2016) Adherence to common cardiovascular medications in patients with schizophrenia vs. Pandi Perumal. U. Lodge. Progress in Neuro-Psychopharmacology and Biological Psychiatry 70, 170-218. Chiu, Yu-Tao Xiang. (2015) Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. Balu. CrossRef 261 Wen-Yu Hua, Debashis Ghosh. A Correction Has Been Published Original Article Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia Jeffrey A. CrossRef 145 Norman Jay Stomski, Paul Morrison, Amanda Meyer. Cohen, P. Over 20 resume templates that are polished and popular. (2017) The real-life effectiveness of psychosocial therapies on social autonomy in schizophrenia patients: Results from a nationwide cohort study in France. First, Jeffrey A. Brown, James Schuster, Jane Kogan. (2015) Drug repurposing and emerging adjunctive treatments for schizophrenia. International Journal of Mental Health Nursing 24:2, 104-111. (2015) Nursing Care for Lifestyle Behavioral Change. (2015) Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. Khawaja. (2016) A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Citrome, R. Lewis, P. CrossRef 51 Xudong Cao, Yin Chen, Yifang Zhang, Yinli Qiu, Minquan Yu, Xiangqing Xu, Xin Liu, Bi-Feng Liu, Guisen Zhang. Gagnon, Subha Chittamooru, Elizabeth V. CrossRef 397 Alan M Laties, Allan J Flach, Irina Baldycheva, Ihor Rak, Willie Earley, Sanjeev Pathak. The Journal of Nervous and Mental Disease 204:8, 578-584. Psychiatric Epidemiology. Estimates are from a mixed model, which assumed that data were missing at random. CrossRef 368 Nicole Ganzer, Brandon Utter, Beth DeJongh, Michael Behrens, Guadalupe Garcia, Rebecca Graham. 14 to 15 percent). (2015) Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. CrossRef 320 Marco Colizzi, Rosalia Costa, Francesca Scaramuzzi, Claudia Palumbo, Margarita Tyropani, Valeria Pace, Luca Quagliarella, Francesco Brescia, Lilia Carmen Natilla, Giuseppe Loverro, Orlando Todarello. (2015) New treatments for psychotic disorders. Cook. Kane, Jim van Os, Thomas R. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. 5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1. CrossRef 91 Eduard Parellada, Miquel Bioque. Adobe Flash Player is required to view this feature. CrossRef 234 Satomi Nimura, Tomohiro Yamaguchi, Koki Ueda, Karin Kadokura, Toshihiro Aiuchi, Rina Kato, Takashi Obama, Hiroyuki Itabe. Van Dorn, K. CrossRef 120 B. Two hundred thirty-one patients with tardive dyskinesia were excluded from random assignment to perphenazine. Lane, A. Citing Articles 1 Emmert Roberts, Leah Jones, Alexandra Blackman, Thomas Dewhurst, Faith Matcham, Carol Kan, Omar Mustafa, Toral Thomas, Najma Siddiqi, Khalida Ismail, Hermione Price.

[img][/img]
Wong, Frank M. International Journal of Psychiatry in Clinical Practice 20:2, 54-69. Adobe Flash Player is required to view this feature. Kane, Ema Saito, Christoph U. Bargiota, Danai Kirla, Eirini Rera, Georgios Garyfallos. (2016) Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5. Denaxas, C. (2015) Urine testing for antipsychotics: a pilot trial for a method to determine detection levels. Love, Yiyun Wang, David Heal. Eden Evins, Ann McNeill, Debbie Robson. N. Harte. Mallar Chakravarty, Ridha Joober, Martin Lepage. CrossRef 140 Wai Shing Tse, Ann Siu Wah Wong, Fu Chan, Alfred Hin Tat Pang, Alyson Jane Bond, Chau Kiu Raymond Chan. CrossRef 29 R. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. The dose range of perphenazine was chosen to minimize the potential for extrapyramidal symptoms that may have biased previous comparisons of first- and second-generation drugs. (2016) The Integral Role of Psychoeducation in Clinical Care. Breggin. C. Timmermans, P. Peter, P. (Accessed August 26, 2005, at ) 22 Tunis SR, Stryer DB, Clancy CM. (2016) SZDB: A Database for Schizophrenia Genetic Research. CrossRef 54 Giovanni Ostuzzi, Irene Bighelli, Ryuhei So, Toshi A. (2017) A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia. Reeves, James Teufel, Teodor T. (2015) Effectiveness and Predictors of Continuation of Paliperidone Palmitate Long-Acting Injection Treatment. Vernon. Sivarao, Amy Easton, Alda Fernandes, Michael Gulianello, Umesh M. CNS Drugs. (2015) Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. CrossRef 316 T. CrossRef 181 Cai-Lan Hou, Yu Zang, R. Hess. R. CrossRef 213 Peter R. Grace. Guarino, Kimberly Weingart, Ilanit Tal Young, Jean Yoon, Theresa C. Braff. Zhurnal nevrologii i psikhiatrii im. Gibbons, Anton Kolotilin, Anna Levine Taub. (2015) Gender differences in antipsychotics prescribed to veterans with serious mental illness. Correll. , inefficacy or intolerability owing to side effects such as weight gain, extrapyramidal signs, or sedation as judged by the study doctor). If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Desmarais, S. Lawrence, Mary LeGwin, Sidney Zisook. Scores for the PANSS can range from 30 to 210, with higher scores indicating more severe psychopathology. (2016) Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Khan. Adobe Flash Player is required to view this feature. Bozikas, Eleni Parlapani, Vasiliki Holeva, Eleni Skemperi, Stavroula I. Holmquist, Janet Forst, Xia Wang, Niek Dekker, Clay W. D. European Archives of Psychiatry and Clinical Neuroscience 266:5, 397-407. CrossRef 282 Mehmet E. Choosing Psychiatric Medications for Patients with Severe Obesity and Pharmacological Treatments for Severe Obesity in Patients with Psychiatric Disorders: A Case Study. Light. (2015) Neuromodulation Treatments for Schizophrenia. (2015) Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. Volavka, R. Adobe Flash Player is required to view this feature. CrossRef 121 Cenk Tek, Suat Kucukgoncu, Sinan Guloksuz, Scott W. (2015) Clinical management of negative symptoms of schizophrenia: An update. Service Business Model Innovation in Healthcare and Hospital Management, 111-135. CrossRef 104 Tyrone D. A. Barbui. Besag, Esther W. (2015) Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents. CrossRef 236 Stefan Leucht, Myrto Samara, Stephan Heres, Maxine X. Harvey, Ofer Agid, Mary Waye, Carla Brambilla, Wing-Kit Choi, Gary Remington. Gaughran. Ter-israelyan. Overlap in the administration of the antipsychotic agents that patients received before study entry was permitted for the first four weeks after randomization to allow a gradual transition to study medication. (2015) Measurement of Metabolic Monitoring in Youth and Adult Medicaid Recipients Prescribed Antipsychotics. 2017. CrossRef 4 Che-Sheng Chu, Po-Han Chou, Yi-Huei Chen, Min-Wei Huang, Min-Yen Hsu, Tsuo-Hung Lan, Ching-Heng Lin. S. (2016) Individualized metacognitive therapy for delusions: A randomized controlled rater-blind study. (2016) Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. 2016. (2015) A pharmacogenomic study revealed an association between. (2015) Recovery from psychosis: physical health, antipsychotic medication and the daily dilemmas for mental health nurses. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 33 Hiroyoshi Takeuchi, Gagan Fervaha, Gary Remington. Dibben, G. Roy, J. Sommer. Bereza, Kristel Van Impe. 5 to 6. -X. Merrill, L. Clish, Rakesh Karmacharya. M. In the wake of this trend, questions have been raised about the clinical advantages and cost effectiveness of the atypical drugs. Jefferies, K. Room, O. In contrast to previous studies, 35 the proportion of patients with extrapyramidal symptoms did not differ significantly among those who received first-generation and second-generation drugs in our study. S. (2016) Short term effectiveness of haloperidol versus risperidone in first-episode schizophrenia. -A. (2015) Schizophrenia. (2015) Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis. Medvedev, V. Kawula, Maureen A. Conort, B. Adobe Flash Player is required to view this feature. Huys, Marc Guitart-Masip, Raymond J. CrossRef 280 Hsue-Wei Chan, Chin-Yu Huang, Wen-Jui Feng, Yung-Chieh Yen. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Farrington, H. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. CrossRef 318 Benedetto Vitiello. CrossRef 84 Young Sup Woo, Won-Myong Bahk, Young-Min Park, Sangkeun Chung, Bo-Hyun Yoon, Seunghee Won, Jeong Goo Lee, Hwang-Bin Lee, Won Kim, Jong-Hyun Jeong, Kwanghun Lee, Moon-Doo Kim. (2014) The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse. Babigumira. CrossRef 23 Yanling Zhou, Robert Rosenheck, Somaia Mohamed, Yuping Ning, Hongbo He. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Easy Follow few steps to make a free professional resume in just minutes. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. 2016. CrossRef 287 Elana Schwartz, Melanie Charlotte, Eric Slade, Deborah Medoff, Lan Li, Lisa Dixon, Amy Kilbourne, Julie Kreyenbuhl. Treatment groups were compared with use of proportional-hazards regression. (2016) ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. In summary, patients with chronic schizophrenia in this study discontinued their antipsychotic study medications at a high rate, indicating substantial limitations in the effectiveness of the drugs. Mazurek. (2015) The Other 23 Hours: A Qualitative Study of Fitness Provider Perspectives on Social Support for Health Promotion for Adults with Mental Illness. (2017) Medical Comorbidity in Bipolar Disorder: The Link with Metabolic-inflammatory Systems. (2015) Detection and treatment of at-risk mental state for developing a first psychosis: making up the balance. Van Dorn. Sarris, Yehuda Herschman, Nitin Agarwal, Antonios Mammis. Article Activity 2470 articles have cited this article Article Antipsychotic drugs have become the cornerstone of treatment for schizophrenia. G. (2015) Re-implementation of a pharmacist-managed metabolic syndrome clinic in an outpatient mental health clinic setting. Shackleford, D. (2015) Relationship Between Symptomatic Improvement and Overall Illness Severity in Patients With Schizophrenia. (2015) Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data. Scores for the CGI Scale can range from 1 to 7, with higher scores indicating a greater severity of illness. (2017) The prevalence of diabetes mellitus and abnormal glucose metabolism in the inpatient psychiatric setting: A systematic review and meta-analysis. (2016) Implementation of a Reverse Colocation Model: Lessons from Two Community Behavioral Health Agencies in Rural Pennsylvania. CrossRef 200 Harold E. 2016. Journal of Psychiatric and Mental Health Nursing 22:3, 192-198. (2016) Factors Affecting Medication Adherence Among Adults with Schizophrenia: A Literature Review. Schizophrenia and Other Psychoses. (2015) A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model. Wolfgang Fleischhacker, Jan Volavka. Donohue. A. Khanom, S. Chen, D. Time was classified into months (1, 3, 6, 9, 12, 15, and 18). Patil, P. (2016) Schizophrenia and neurosurgery: A dark past with hope of a brighter future. (2016) Clinical factors related to schizophrenia relapse. Manu, L. Miller, P. (2016) Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years. Banks, H. Adobe Flash Player is required to view this feature. Adams. CrossRef 292 Margaret Knight, Paula Bolton, Catherine Coakley, Lynne Kopeski, Karen Slifka. Woods, Todd Constable, Tyrone D. Cannon. The Journal of Nervous and Mental Disease 203:7, 486-492. Shiers, B. The World Journal of Biological Psychiatry 16:1, 22-30. Adobe Flash Player is required to view this feature. (2016) Antipsychotic prescribing and its correlates in New Zealand. CrossRef 21 Aminata Ali, Arnaud Carre, Massimiliano Orri, Mathieu Urbach, Caroline Barry, Christine Hassler, Bruno Falissard, Sylvie Berthoz, Clementine Nordon. , Robert A. CrossRef 50 A. (2015) Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. All data from one site (33 patients) were excluded before analysis, owing to concern about the integrity of data from that site before the end of the study and before unblinding. (2015) Practical Clinical Trials in Psychopharmacology. (2015) Clinical and Functional Outcomes in People With Schizophrenia With a High Sense of Well-Being. (2015) Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice. CrossRef 114 Abigail I. (2015) Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. Lieberman, M. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2015) Perceived risk of relapse and role of medication: comparison between patients with psychosis and their caregivers. Jamal, Bernard. (2015) The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. Arnold, James M. Lebovitz. Panicker. CrossRef 107 David B. 2016. (2015) The Drug Adherence and Treatment Effect of the Paliperidone Long Acting Injection. (2015) Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. (2015) Preventing crime in cooperation with the mental health care profession. K. CrossRef 337 Kathleen L. C. (2016) A population-based study of the comparative effectiveness of second-generation antipsychotics vs older antimanic agents in bipolar disorder. Journal of Social Work Practice in the Addictions 15:2, 165-184. M. ResumeList resume builder is a new way to build, design and distribute. Timmis, S. CrossRef 301 Mike Skelton, Waqqas Ahmad Khokhar, Simon P Thacker, Mike Skelton. Blais, J. (2016) Evaluation of genetic association of neurodevelopment and neuroimmunological genes with antipsychotic treatment response in schizophrenia in Indian populations. Maidment. R. If the difference was significant at a P value of less than 0. H. (2016) Incidence of Antipsychotic-Associated Side Effects. CrossRef 353 Richard Musil, Michael Obermeier, Paul Russ, Michael Hamerle. (2015) Antipsychotics and Amotivation. (2014) Healthcare Utilization and Costs of Veterans Health Administration Patients with Schizophrenia Treated with Paliperidone Palmitate Long-Acting Injection or Oral Atypical Antipsychotics. Adobe Flash Player is required to view this feature. CrossRef 279 P. Journal of Psychiatric and Mental Health Nursing 22:7, 549-557. Rofatto, Adhemar Zerlotini, Eliana Nakano, Guilherme Oliveira, Sergio Verjovski-Almeida, Robert M Greenberg. C. Carrier, A. (2015) Insight and subjective measures of quality of life in chronic schizophrenia. Adobe Flash Player is required to view this feature. (2016) Reason for Clozapine Discontinuation. Patients with tardive dyskinesia were not assigned to perphenazine. CrossRef 55 Seher Karsli-Ceppioglu. Modeling the Psychopathological Dimensions of Schizophrenia - From Molecules to Behavior, 107-124. S. T. Neuropathology of Drug Addictions and Substance Misuse, 82-88. (2016) A regulatory perspective on missing data in the aftermath of the NRC report. CrossRef 41 George Awad, Daisy Ng-Mak, Krithika Rajagopalan, Jay Hsu, Andrei Pikalov, Antony Loebel. CrossRef 61 Max Tsai, Lambros Chrones, Jinhui Xie, Hakop Gevorkyan, Thomas A. International Journal of Mental Health Nursing 24:3, 253. (2016) Liberty versus Need — Our Struggle to Care for People with Serious Mental Illness. CrossRef 257 Jennifer Miller, Heidi Wehring, Robert P. Lage, Leticia Anderson, Thiago M. Weight Gain and Metabolic Changes Patients in the olanzapine group gained more weight than patients in any other group, with an average weight gain of 2 lb (0. Correll, Josephine Cucchiaro, Robert Silva, Jay Hsu, Andrei Pikalov, Antony Loebel. Synaptic Abnormalities and Neuroplasticity. (2016) Detecting and Managing Adverse Effects of Antipsychotic Medications. (2016) Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder. Moore, D. (2017) Association between antipsychotic drug use and cataracts in patients with bipolar disorder: A population-based, nested case-control study. Samara, Chunbo Li, Siegfried Kasper, Stefan Leucht. Roussos, S. Leweke, S. Degnan. (2015) Motivational deficits in early schizophrenia: Prevalent, persistent, and key determinants of functional outcome. CrossRef 383 Tarek Okasha, Ash-Shayma Radwan. Grimm. CrossRef 131 Peggy El-Mallakh, Jan Findlay. CrossRef 141 Hao Yu, Lifang Wang, Luxian Lv, Cuicui Ma, Bo Du, Tianlan Lu, Chao Jin, Hao Yan, Yongfeng Yang, Wenqiang Li, Yanyan Ruan, Hongyan Zhang, Hongxing Zhang, Weifeng Mi, Bryan Mowry, Wenbin Ma, Keqing Li, Dai Zhang, Weihua Yue. Journal of Psychiatric and Mental Health Nursing 22:3, 157-170. Korsakova 115:8, 28. 2015. Dysregulation of Dopamine Systems in a Developmental Disruption Model of Schizophrenia. P. Mistry, R. J. CrossRef 117 Po-Han Chou, Che-Sheng Chu, Ching-Heng Lin, Chin Cheng, Yi-Huey Chen, Tsuo-Hung Lan, Min-Wei Huang. 2016. Kahn, I. CrossRef 168 Christoffer Polcwiartek, Kristian Kragholm, Ole Schjerning, Claus Graff, Jimmi Nielsen. (2015) Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. Yudofsky. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Bedouch, O. The World Journal of Biological Psychiatry 17:3, 221-229. Rates. Courteau, A. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Fast Follow few steps to make a free professional resume in just minutes. Simon. 20 to 25 percent, P Neurologic Side Effects There were no significant differences among the groups in the incidence of extrapyramidal side effects, akathisia, or movement disorders as reflected by rating-scale measures of severity. (2016) Improving Treatment Adherence in Schizophrenia. Kahn, W. Han. CrossRef 176 Mong-Liang Lu, Yi-Xiu Wu, Chun-Hsin Chen, Pei-Ting Kuo, Yi-Hua Chen, Chia-Hui Lin, Tzu-Hua Wu, Peter John McKenna. 2015. V. Lapane, John Fastenau. Increasing antipsychotic dose for non response in schizophrenia. 4,7,31 The use of low-dose perphenazine appears to have diminished the frequency of extrapyramidal side effects in patients who received the first-generation drug. Butler, Joan C. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Because of product labeling, quetiapine and ziprasidone are given twice daily and olanzapine, perphenazine, and risperidone once daily. E. (2016) Resilience in Patients With Recent Diagnosis of a Schizophrenia Spectrum Disorder. (2015) Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia. (2015) Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. CrossRef 95 Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Atsuhiko Takaya. CrossRef 358 Harin Kim, Jungsun Lee, Changyoon Kim, Yeonho Joo. Gur, David L. (2015) Evaluating subjective domains of antipsychotic-induced adverse effects using heart rate variability. (2016) Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. Malone, S. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Christopoulos. Mutamba, Angelo Nganizi, Joseph B. Larouche, S. Sugarman, Ashley Wennerstrom. CrossRef 215 Caroline Faour-Nmarne, Abed N Azab. -D. Love, Ayodele Antoinette Morris, Heather Raley, Stephanie Feldman, Deanna L. CrossRef 271 Eric M. 2015. Modeling Psychiatric Disorders in Experimental Animals. CrossRef 216 Vishal Ahuja, John R. (2015) Antipsychotic Prescribing. (2016) Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment. (2016) Are all first-generation antipsychotics equally effective in treating schizophrenia. Carpenter-Song, S. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Dokucu. George Awad, Lakshmi N. 2015. 31 Only a minority of patients in each group took their assigned drug for the duration of phase 1 (rates of discontinuation ranged from 64 to 82 percent). 2015. J. CrossRef 210 J. CrossRef 40 Lorenz Deserno, Andreas Heinz, Florian Schlagenhauf. (2016) Unbiased Metabolite Profiling of Schizophrenia Fibroblasts under Stressful Perturbations Reveals Dysregulation of Plasmalogens and Phosphatidylcholines. Anaya-Izquierdo, A. K. (2015) Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach. Siva Selva Kumar, M. CrossRef 172 Nobuto Tsuneyama, Yutaro Suzuki, Kazushi Sawamura, Takuro Sugai, Naoki Fukui, Junzo Watanabe, Shin Ono, Mami Saito, Toshiyuki Someya, Susanne Kaser. Epigenetic Approaches to Define the Molecular and Genetic Risk Architectures of Schizophrenia. J. Its apparent superior efficacy is also indicated by the greater reduction in psychopathology, longer duration of successful treatment, and lower rate of hospitalizations for an exacerbation of schizophrenia. McEvoy, M. CrossRef 109 Antonio Maone. (2016) Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. CrossRef 133 Graham Dunn. 2015. CrossRef 74 Richard Whale, Michael Harris, Gail Kavanagh, Vijitha Wickramasinghe, Christopher I. P. Scores for the CGI Scale can range from 1 to 7, with higher scores indicating a greater severity of illness. CrossRef 225 Dena R Cohen, Susan Todd, Walter M Gregory, Julia M Brown. (2016) Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine. 2017. Lawler. CrossRef 290 Peter R. (2017) The Harms of Antipsychotic Drugs: Evidence from Key Studies. Adobe Flash Player is required to view this feature. CrossRef 264 Maren Carbon, Sandeep Kapoor, Eva Sheridan, Aseel Al-Jadiri, Sally Azzo, Tania Sarkaria, John M. T. Wendt, T. CrossRef 354 Emanuel Schwarz, Johann Steiner, Paul C. CrossRef 221 Yamato Kato, Ryogo Umetsu, Junko Abe, Natsumi Ueda, Yoko Nakayama, Yasutomi Kinosada, Mitsuhiro Nakamura. Malhotra, Todd Lencz. (2015) Weight gain and antipsychotics: a drug safety review. Des